Literature DB >> 25800722

Tumour staging of oesophageal cancer in the Swedish Cancer Registry: A nationwide validation study.

Nele Brusselaers1, Andreas Vall, Fredrik Mattsson, Jesper Lagergren.   

Abstract

BACKGROUND: Tumour stage was introduced to the Swedish Cancer Registry in 2004, but this key variable for prognostic research has not yet been validated. We validated the tumour stage data in surgically treated oesophageal cancer patients.
MATERIAL AND METHODS: Completeness and accuracy of tumour stage according to the TNM system ("Tumour Node Metastasis") in the Cancer Registry were compared with a cohort study including comprehensive tumour stage data based on the pathological TNM of almost all patients operated for oesophageal cancer in 2006-2010 in Sweden.
RESULTS: Of the 397 patients with pathological TNM data in the comparison cohort, the Cancer Registry reported an overall TNM stage in 390 patients (98.2%), which was based on the pathological TNM of 104 patients (26.2%), the clinical TNM of 183 patients (46.1%), and the pathological or clinical TNM (undefined) of 110 patients (27.7%). The completeness for the separate T, N, and M components was 89.4%, 90.9%, and 85.1%, respectively. The concordance with tumour stage was 98.2%, while it was 51.1%, 70.5%, and 80.4% for the separate T, N, and M components, respectively. While the concordance with tumour stage was high for all TNM assessment groups (98.1-98.4%), the concordance of the T and N components was highest when using pathological TNM (82.7% and 95.2%, respectively), and the concordance of the M component was highest when using clinical TNM (88.5%).
CONCLUSION: Although the overall completeness of tumour stage is high, the recording of pathological TNM stage and individual components could be improved within the Swedish Cancer Registry.

Entities:  

Mesh:

Year:  2015        PMID: 25800722     DOI: 10.3109/0284186X.2015.1020968

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  7 in total

1.  Risk of Esophageal Adenocarcinoma After Antireflux Surgery in Patients With Gastroesophageal Reflux Disease in the Nordic Countries.

Authors:  John Maret-Ouda; Karl Wahlin; Miia Artama; Nele Brusselaers; Martti Färkkilä; Elsebeth Lynge; Fredrik Mattsson; Eero Pukkala; Pål Romundstad; Laufey Tryggvadóttir; My von Euler-Chelpin; Jesper Lagergren
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777

2.  Cohort profile: the Swedish Pancreatitis Cohort (SwePan).

Authors:  Daniel Selin; Bei Yang; Mats Lindblad; Urban Arnelo; Magnus Nilsson; Omid Sadr-Azodi; John Maret-Ouda
Journal:  BMJ Open       Date:  2022-05-27       Impact factor: 3.006

3.  Cohort profile: the Nordic Antireflux Surgery Cohort (NordASCo).

Authors:  John Maret-Ouda; Karl Wahlin; Miia Artama; Nele Brusselaers; Martti Färkkilä; Elsebeth Lynge; Fredrik Mattsson; Eero Pukkala; Pål Romundstad; Laufey Tryggvadóttir; My von Euler-Chelpin; Jesper Lagergren
Journal:  BMJ Open       Date:  2017-06-08       Impact factor: 2.692

4.  Survival Trends in Gastric Adenocarcinoma: A Population-Based Study in Sweden.

Authors:  Johannes Asplund; Joonas H Kauppila; Fredrik Mattsson; Jesper Lagergren
Journal:  Ann Surg Oncol       Date:  2018-07-09       Impact factor: 5.344

5.  The Korea Cancer Big Data Platform (K-CBP) for Cancer Research.

Authors:  Hyo Soung Cha; Jip Min Jung; Seob Yoon Shin; Young Mi Jang; Phillip Park; Jae Wook Lee; Seung Hyun Chung; Kui Son Choi
Journal:  Int J Environ Res Public Health       Date:  2019-06-28       Impact factor: 3.390

6.  Dynamic monitoring of plasma amino acids and carnitine during chemotherapy of patients with alimentary canal malignancies and its clinical value.

Authors:  Xiaoyu Wang; Jiaqi Wang; Zhenghua Wang; Qingjun Wang; Hua Li
Journal:  Onco Targets Ther       Date:  2015-08-07       Impact factor: 4.147

7.  Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study.

Authors:  Joonas H Kauppila; Fredrik Mattsson; Nele Brusselaers; Jesper Lagergren
Journal:  BMJ Open       Date:  2018-05-10       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.